PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3410932-4	1988	The prednisone-treated group had higher mean plasma levels of triglyceride [2.06 +/- 1.3 (+/- SD) vs. 1.15 +/- 0.35 and 0.95 +/- 0.46 mmol/L; P less than 0.01], low density lipoprotein cholesterol [3.41 +/- 1.4 (+/- SD) vs. 2.79 +/- 0.67 and 2.84 +/- 0.70 mmol/L; P less than 0.01], and apoB [1.16 +/- 0.35 (+/- SD) vs. 0.82 +/- 0.13 and 0.76 +/- 0.22 g/L] than the other 2 groups.	Prednisone	4-14	apolipoprotein B	Homo sapiens	287-291	
30996113-7	2019	For ApoB rs693, mutation increased the incidence of SONFH in prednisone-use and methylprednisolone/prednisolone-use populations and renal transplant patients.	Prednisone	61-71	apolipoprotein B	Homo sapiens	4-8	
30996113-8	2019	For ApoB rs1042031, mutation increased the risk of SONFH in the prednisone-use population.	Prednisone	64-74	apolipoprotein B	Homo sapiens	4-8	
11092996-6	2000	In the multiple regression test, a linear coincidence was observed between apo A1, apo B and prednisone cumulative dosage after the 1st month, TG and cyclosporine in the 6th month and LDL and cyclosporine in the 12th month after transplantation.	Prednisone	93-103	apolipoprotein B	Homo sapiens	83-88	
3410932-5	1988	Forty-three percent of the prednisone-treated group had apoB levels of 1.20 g/L or more compared to 7% of normal subjects and none of the untreated SLE group (P less than 0.05).	Prednisone	27-37	apolipoprotein B	Homo sapiens	56-60	
3410932-6	1988	However, of the 12 prednisone-treated patients with elevated plasma apoB levels 5 had normal plasma lipid levels.	Prednisone	19-29	apolipoprotein B	Homo sapiens	68-72